Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ipsen SA and Active Biotech AB Initiate Phase II Switch Maintenance Trial in Metastatic Castrate-resistant Prostate Cancer with Tasquinimod


Wednesday, 3 Oct 2012 12:45pm EDT 

Ipsen SA and Active Biotech AB announced the initiation of a new phase II proof of concept clinical trial, evaluating the activity of tasquinimod in advanced metastatic castrate resistant prostate cancer patients. The study aims at establishing the clinical efficacy of tasquinimod used as maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have not progressed after a first line docetaxel based chemotherapy. The "switch maintenance" trial is part of the initial agreement with Active Biotech to enhance tasquinimod's data package beyond the ongoing phase III placebo-controlled study in men with bone-metastatic CRPC, which has been adequately powered to detect an OS improvement. 

Company Quote

32.7
0.4 +1.24%
29 Aug 2014